Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
Infographics
-
Expand to See More
EACS Congress 2025 Infographic
Have you Heard? Infographic
IAS Congress 2025 Infographic
HIV Glasgow Congress infographic
PASO DOBLE Infographic
5-Years of Dovato Infographic
SALSA 48-Week Update Infographic
STAT 48-Week Infographic
Patient Resources
-
Expand to See More
Dovato Post Prescription Tear Off Pad - Switch Patient
A tear off leaflet to be given to a PLHIV who has been switched to Dovato from another treatment option.
Download Dovato Post Prescription Tear Off Pad - Switch Patient Order via Email
Dovato Post Prescription Tear Off Pad (Brazilian Portuguese) - Switch Patients
A tear off leaflet in Brazilian Portuguese to be given a PLHIV who has been switched to Dovato from another treatment option.
Download Dovato Post Prescription Tear Off Pad (Brazilian Portuguese) - Switch Patients Order via Email
Dovato Post Prescription Tear Off Pad - Naïve Patient
A tear off leaflet to be given to a PLHIV who has been initiated on Dovato following a new diagnosis.
Download Dovato Post Prescription Tear Off Pad - Naïve Patient Order via Email
Dovato Post Prescription Tear Off Pad (Brazilian Portuguese) - Naive Patient
A tear off leaflet in Brazilian Portuguese to be given to a PLHIV who has been initiated on Dovato following a new diagnosis.
Download Dovato Post Prescription Tear Off Pad (Brazilian Portuguese) - Naive Patient Order via Email
Dovato Post Prescription Patient Information Booklet
A printed A6 booklet to provide practical information for patients post-prescription of Dovato.
POM. Further information is available from GlaxoSmithKline (Ireland) Ltd
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255, or via the online patient safety reporting form at gsk.public.reportum.com.
Dovato is a registered trade mark of the ViiV Healthcare group of companies or its licensor.
Date of preparation: January 2026 | PM-IE-DLL-WCNT-250008
